Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638667 | 0.91 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PDE4A | |
| SCHEMBL6640155 | 0.85 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11PDE4A | |
| SCHEMBL27573094 | 0.83 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1993317 | 0.80 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6640304 | 0.80 | MAPK14 (1.00) | MAPK14PDE4A | |
| SCHEMBL6640633 | 0.76 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PDE4A | |
| SCHEMBL6641727 | 0.76 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11PDE4A | |
| SCHEMBL6642816 | 0.75 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11PDE4A | |
| SCHEMBL2889128 | 0.74 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11PDE4A | |
| SCHEMBL5639664 | 0.72 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | claimed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | claimed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | claimed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | claimed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | claimed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | claimed |
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
| US-20030139462-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885MAPK13 33/4885MAPK12 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.